Exemestane Plus Everolimus for Hormone-receptor Positive Metastatic Breast Cancer

Hormone Receptor Positive Malignant Neoplasm of Breast Clinical Trial

Official title:

A Phase II Open-label Pilot Study Evaluating the Maintenance Therapy With Exemestane Plus Everolimus After Induction Chemotherapy in Patients With Hormone-receptor Positive Metastatic Breast Cancer

Clinical Trial Details — Status: Not yet recruiting

Administrative data

• NCT number: NCT02025712
• Other study ID #: M004/EXE-EVE
• Status: Not yet recruiting
• Phase: Phase 2
• First received: December 16, 2013
• Last updated: December 29, 2013

Study information

• Verified date: December 2013
• Source: Organisation for Oncology and Translational Research
• Contact: Louis Chow, MD
• Phone: (852)28610286
• Is FDA regulated: No
• Health authority: Hong Kong: Department of Health
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is to determine whether exemestane plus everolimus are effective in the treatment of patients who have achieved disease stabilization after induction chemotherapy for hormone-receptor positive metastatic breast cancer.

Description:

Postmenopausal women with HR-positive, HER2-negative metastatic breast cancer achieving clinical benefit after the induction chemotherapy for visceral disease with sign(s) and/or symptom(s) will be recruited to receive study the maintenance treatment of everolimus plus exemestane.

Recruitment information / eligibility

• Status: Not yet recruiting
• Enrollment: 35
• Est. primary completion date: August 2016
• Accepts healthy volunteers: No
• Gender: Female
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Postmenopausal women as defined in the protocol page 9;

• Histologically and/or cytologically confirmed invasive breast cancer with stage IV disease according to AJCC;

• Confirmed ER/PR-positive, and HER-2 negative tumor;

• Disease progression on or following prior endocrine therapy with tamoxifen or non-steroidal aromatase inhibitor, as defined in protocol, prior to standard of care (SOC) induction chemotherapy

• Patient with documented evidence of visceral disease (including but not limited to hepatic involvement and pulmonary lymphangitic spread of tumor) with sign(s) and/or symptom(s) prior to SOC induction chemotherapy should achieve disease stabilization after the SOC induction chemotherapy, confirmed upon 2 consecutive routine tumor assessments;

• ECOG performance status = 2 or Karnofsky performance status = 50% prior to the start of study treatment;

• Adequate organ function prior to the start of study treatment as defined in the protocol;

• Able to swallow and retain oral medication;

• Able to give written informed consent;

Exclusion Criteria:

• Male patient;

• Metastatic disease limited to the bone or soft tissues only and with no history of other visceral metastases;

• History of brain or other CNS metastases;

• Previous treatment with exemestane, unless exemestane was administered in the adjuvant setting and stopped >1 year before metastatic relapse;

• Untreated with SOC chemotherapy for invasive breast cancer with stage IV disease according to AJCC - or - treated with SOC chemotherapy for invasive breast cancer with stage IV disease according to AJCC without clinical benefit;

• History of neurological or psychiatric disorders;

• Any serious cardiovascular diseases in the previous 6 months;

• Impairment of gastrointestinal function or gastrointestinal disease;

• Patients with uncontrolled infection;

• Patients with an active, bleeding diathesis or on oral anti-vitamin K medication (except low dose coumadin defined as 1 mg a day);

• Chronic treatment with systemic steroids or another immunosuppressive agent;

• Patients with a pre-existing peripheral neuropathy > grade 1;

• Patients who are hepatitis B and/or hepatitis C carriers;

• Known human immunodeficiency virus infection;

• Prior exposure to mTOR inhibitors;

• Hypersensitivity to rapamycin or other similar compounds;

• Patients taking medications known to be inhibitors or inducers of CYP3A4 and/or PgP will not be included in this study;

• Prior treatment with any investigational agent within the preceding 4 weeks;

• Other conditions in the judgment of the investigator, would make the patient inappropriate for entry into this study.

Other protocol-defined inclusion/exclusion criteria may apply.

Study Design

Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

• Breast Neoplasms
• Hormone Receptor Positive Malignant Neoplasm of Breast
• Neoplasms

Intervention

Drug:
• Exemestane
Commercially available exemestane was supplied to sites as 25-mg tablets according to local regulations.
• Everolimus
Everolimus was administered by continuous oral dosing of two 5-mg tablets or one 10-mg tablets.

Locations

Country	Name	City	State
China	Unimed Medical Institute	Hong Kong

Sponsors (1)

Lead Sponsor	Collaborator
Organisation for Oncology and Translational Research

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Progression Free Survival	defined as from date of treatment initiation with everolimus plus exemestane to the date of progression or death if no documented disease progression	Every 8 weeks in the first 24 weeks of treatment and every 12 weeks thereafter, up to 8 months (estimated)	No
Secondary	Response rate		Every 8 weeks, up to 8 months (estimated)	No
Secondary	Clinical benefit rate		Every 8 weeks, up to 8 months (estimated)	No
Secondary	Overall survival		date of treatment initiation with everolimus plus exemestane until the date of death, censored at the last date known alive, whichever came first, assessed up to 32 months	No
Secondary	Incidence of Adverse Events (AEs)/Serious Adverse Events (SAEs)		Continuous during the study, up to 28 days after the last treatment	Yes